A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Summary

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.

Timeline

Start

2022-04-14

Primary completion

2025-08

Completion

2025-11

Drugs

Indications